Researchers found that high doses of the novel antisense oligonucleotide were associated with lower concentrations of mutant huntingtin protein in the cerebrospinal fluid and brain.
Interventions aimed at motor and cognitive impairments in Huntington disease may result in long-term functional improvement.
Research has shown significant gaps in knowledge on palliative services among neurology residents, resulting in low referral rates.
Investigators examined blood plasma samples taken annually from a cohort of 201 huntingtin gene (HTT) carriers.
Early onset of motor symptoms related to substance abuse appeared to significantly affect women compared with men.
Deutetrabenazine is only the second drug approved for patients with Huntington's disease.
The study supports the need for clinicians to initiate genetic counseling in patients who show clinical signs of HD.
The drug has a similar mechanism of action as tetrabenazine, but a different pharmacokinetic profile.
The HD-associated CAG repeat with 36 or more repeats was found in 18 individuals.
A new drug that inhibits the production of HTT mRNA may help slow progression of Huntington's disease.
The FDA has granted Orphan Drug designation to IONIS-HTT (Ionis) for the treatment of Huntington's disease.
Addressing proteasome dysfunction may help prevent accumulation of the toxic protein.
The FDA has accepted an application for SD-809 (deutetrabenazine) for the treatment of chorea associated with Huntington's disease.
With no control group, researchers also considered that the positive response was a placebo effect.
Patients with bvFTD are more likely to exhibit criminal behavior like theft and public urination.
Neurology Advisor Articles
- Higher Levels of Cholesterol May Protect Men From Parkinson Disease
- Early Clinical Traits of Multiple Sclerosis Prodrome Identified
- Chronic Pain May Be Contributor to Suicide
- FDA Approves Tiglutik for the Treatment of Amyotrophic Lateral Sclerosis
- Ajovy Injection Approved for Migraine Prevention in Adults
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- Brivaracetam Effective for Reducing Seizures in Patients with Epileptic Encephalopathies
- Familial Hemiplegic Migraine Attacks May Be Associated With Cortical Swelling
- Natalizumab Improves Cognitive Function in Multiple Sclerosis
- Fremanezumab May Have Long-Term Efficacy as a Prophylactic for Chronic Migraine
- Propofol May Decrease Delay in Neurocognitive Recovery